Liaison(s): Stacy Rudnicki, Amy Laverdiere
The Cytokinetics TMP team was tasked with identification of viable alternative indications for which CK-107 would be efficacious. In order to complete this task, the team has taken into consideration such factors as competition (as measured by clinical trial progress of competitors), viability of drug mechanism, and current standard of care for various disease states, among others. The team is currently in the process of conversing with key opinion leaders in various disease states to obtain accurate, real-world information regarding the current state of affairs in each disease area. Completion of this project has provided Cytokinetics with important information surrounding the benefits/risks of pursuing each indication.